Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ob/Gyn Panel Unanimously Supports Adhesion-Prevention Product Approval

This article was originally published in The Gray Sheet

Executive Summary

Baxter's biosurgery business stands to gain from an FDA advisory panel's unanimous support for a product designed to prevent a serious side effect of certain surgical procedures. But limitations recommended for the label could curb some of the market potential if adopted by the agency in its final approval decision

You may also be interested in...



Tyco Acquires Bio-Sealant Pipeline With $245 Mil. Confluent Surgical Buy

Tyco Healthcare subsidiary U.S. Surgical will acquire Confluent Surgical for $245 mil. to augment its suture business with a pipeline of bioabsorbable sealants

Tyco Acquires Bio-Sealant Pipeline With $245 Mil. Confluent Surgical Buy

Tyco Healthcare subsidiary U.S. Surgical will acquire Confluent Surgical for $245 mil. to augment its suture business with a pipeline of bioabsorbable sealants

FDA Panel To Decide If Adept Adhesion Prevention Device Is True To Its Name

FDA's Obstetrics & Gynecology Devices Panel will consider Innovata's Adept for preventing gynecological laparoscopic surgery-based adhesions at a March 27 meeting in Gaithersburg, Md

Related Content

UsernamePublicRestriction

Register

MT023398

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel